CytomX Therapeutics Inc. (CTMX)
CTMX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1501989/000119312526107146/0001193125-26-107146-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CTMX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2015 |
| SEC CIK | 0001501989 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $76.2M |
| Net income | -$17.4M |
| Operating income | -$22.4M |
| Net margin | -22.8% |
| Operating margin | -29.3% |
| Revenue growth | -44.8% |
| Cash | $12.7M |
| Total assets | $151.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 5.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $34.0M cash; operating cash flow -$12.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 218,004,920 (2026-10-31); 169,435,395 a year earlier; 66,988,904 three years earlier. | Cover page 2026-10-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-03-18 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Francisco, California, United States | PCAOB Form AP 2026-04-02 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $1.7M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $1.7M | -$20.0M | $16.6M | $34.0M | No debt tags | $14.0M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $1.4M | -$20.7M | -$18.1M | $17.2M | No debt tags | $18.3M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $10.3M | -$18.2M | -$25.5M | $28.8M | No debt tags | $35.5M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $663K | -$26.5M | -$23.2M | $12.7M | No debt tags | $76.2M | 10-K 2026-03-16 |
| Q3 2025 2025-09-30 | $6.0M | -$14.2M | -$15.5M | $34.2M | No debt tags | $113.6M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $18.7M | -$154K | -$15.8M | $49.0M | No debt tags | $141.1M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $50.9M | $23.5M | -$21.0M | $47.6M | No debt tags | $147.6M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $38.1M | $18.9M | -$19.9M | $38.1M | No debt tags | $138.1M | 10-K 2026-03-16 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-03-18 |
| Latest annual report | 10-K | 2026-03-16 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 801 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -6.8% |
| 1 month | -12.3% |
| 3 months | -39.1% |
| Year to date | -52.1% |
| 1 year | -47.2% |
| From 52-week high | -69.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BLSM | BlossomHill Therapeutics Inc. | $13.65 | -2.64% | $433.9M |
| ASMB | Assembly Biosciences Inc. | $21.29 | +0.80% | $436.0M |
| EOLS | Evolus Inc. | $6.63 | -4.74% | $438.8M |
| AVTX | Avalo Therapeutics Inc. | $7.37 | -5.03% | $426.2M |
| ARVN | Arvinas Inc. | $6.77 | -0.73% | $443.3M |
| MPLT | MapLight Therapeutics Inc. | $6.90 | -4.83% | $446.9M |
| DMAC | DiaMedica Therapeutics Inc. | $8.33 | -5.23% | $449.5M |
| OVID | Ovid Therapeutics Inc. | $2.40 | -5.51% | $453.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier